Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SISTER Trial: TS23 in Acute Ischemic Stroke
NCT05948566Phase 2Recruiting
- Sponsor
- Translational Sciences, Inc.
- Start
- Mar 2024
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TS23 in ischemic stroke, sponsored by Translational Sciences, Inc.. Started Mar 2024; status: recruiting.
02
Drugs
TS23
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05948566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948566.